IMMX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Mkt Cap

$661.6M

Volume

1.28M

Next Earnings

November 6th

Loading chart

IM

IMMXImmix Biopharma, Inc. Common Stock

IMMX

Pay with—

Available Balance0.00

IM

Mkt Cap

$661.6M

Volume

1.28M

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXPomerantz Law Firm is investigating Immix Biopharma for potential securities fraud after discovering that its newly appointed Chief Medical Officer, Richard Graydon, was actually Ronald L. Fischer, a fugitive wanted for a 2005 rape charge who had evaded authorities for over 20 years. Following the revelation, Immix's stock price dropped 14.15% on July 20, 2026.GlobeNewswire Inc. · Aug 4, 2026

EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their LossesEquipmentShare.com Inc. (EQPT) faces a securities fraud lawsuit after allegedly making false statements about terminating related-party transactions with founder-controlled entities. A short-seller report revealed undisclosed transactions netting founders at least $77 million, causing the stock to plummet 34.5% below its IPO price. Investors who purchased shares between January 23 and June 23, 2026, may be eligible to recover losses.GlobeNewswire Inc. · Jul 24, 2026

Immix Biopharma Investigated by the Portnoy Law FirmThe Portnoy Law Firm has launched an investigation into possible securities fraud at Immix Biopharma after discovering that an executive operating under the alias 'Richard Graydon' was actually Ronald Fischer, a fugitive wanted in Rhode Island. The company terminated the officer on July 17, 2026, claiming the separation was unrelated to his activities. Following the disclosure, Immix's stock price declined approximately 10.83%.GlobeNewswire Inc. · Jul 21, 2026

IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the FirmBlock & Leviton is investigating Immix Biopharma for potential securities law violations after discovering that an executive operating under the name 'Richard Graydon' was actually a Rhode Island fugitive named Ronald Fischer using a false identity. The company terminated the individual on July 17, 2026, stating it was unrelated to his work activities. Immix shares fell approximately 10.83% following the news report.GlobeNewswire Inc. · Jul 20, 2026

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common StockImmix Biopharma closed an underwritten registered offering of 16.78 million shares at $8.94 per share, raising approximately $140.65 million in net proceeds. The financing was led by Morgan Stanley and BofA Securities, with participation from leading U.S. biotechnology institutional investors and mutual funds.GlobeNewswire Inc. · May 22, 2026

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2Immix Biopharma reported a 95% complete response rate (19 of 20 patients) in its NEXICART-2 Phase 2 trial for relapsed/refractory AL Amyloidosis using its CAR-T therapy NXC-201. All four MRD-negative patients from ASH 2025 converted to complete response, with no relapses observed to date. The company plans to initiate a Phase 3 trial in newly diagnosed patients and expects BLA submission by end of March 2027.GlobeNewswire Inc. · May 21, 2026

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsImmix Biopharma successfully closed a $100 million public offering of common stock and pre-funded warrants, raising approximately $93.7 million with support from leading biotechnology institutional investors and mutual funds.GlobeNewswire Inc. · Dec 9, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsImmix Biopharma priced an underwritten offering of common stock and pre-funded warrants, expecting to raise $100 million to fund NXC-201 development and corporate operations through mid-2027.GlobeNewswire Inc. · Dec 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL AmyloidosisImmix Biopharma announced promising Phase 2 clinical trial results for NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis, with a 75% complete response rate and potential to increase to 95%.GlobeNewswire Inc. · Dec 7, 2025

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisImmix Biopharma's CAR-T cell therapy NXC-201 demonstrated positive clinical results in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate and a favorable safety profile.GlobeNewswire Inc. · Dec 16, 2024

to start trading

IM

IMMXImmix Biopharma, Inc. Common Stock

IMMX

Pay with—

Available Balance0.00

Your PositionYou don't own any IMMX yet.

Related Tickers

Earnings